EMA Refused: Syfovre — Apellis Europe B.V.

View source ↗

Summary

The EMA refused to grant marketing authorization for Syfovre (pegcetacoplan) for geographic atrophy associated with age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Geographic Atrophy

Drugs mentioned

• SYFOVRE (pegcetacoplan)

Snippet

Status: Refused. Therapeutic area: Macular Degeneration;Geographic Atrophy. MAH: Apellis Europe B.V.. Decision date: 16/12/2024